Evan J. Lipson, M.D., is a medical oncologist at the Johns Hopkins Kimmel Cancer Center as well as an associate professor of oncology at the Johns Hopkins University School of Medicine. He sees patients in Baltimore and at Sibley Memorial Hospital in Washington, DC.
Dr. Lipson earned his undergraduate degree from the University of Maryland and his medical degree from the Mount Sinai School of Medicine. He completed a residency in internal medicine at the Johns Hopkins University School of Medicine, as well as a fellowship at Hopkins in medical oncology.
Dr. Lipson's clinical expertise is in the treatment of patients with advanced skin cancers, including melanoma, Merkel cell carcinoma, basal cell carcinoma, and skin squamous cell carcinoma, among others.
As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, Dr. Lipson focuses on evaluating novel therapies for patients with high-risk or advanced skin cancer. He is a principal or co-investigator on multiple trials, involving partners from both industry and academia, which focus on the clinical development of antibodies that block the PD-1/PD-L1 pathway. He is collaborating to develop new methods to predict and monitor their therapeutic effects, including nuclear imaging and serum-based molecular markers. Dr. Lipson’s publications include the first description of successful PD-1 re-induction therapy (Clin Can Res 2013), and the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer (JCO 2014, NEJM 2016).
Dr. Lipson is also an internationally-recognized educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs.